<i>- Superior SVR rates with telaprevir across all HCV genotype 1
non-responders and relapser patients and patients with cirrhosis - up to
76% in prior relapsers -</i><i>- PROVE 3 showed 51% and 52% SVR rates in telaprevir-based regimens
compared to 14% in the 48-week control arm</i><i>-</i><i>- Treatment-failure patient population represents the greatest unmet
medical need in HCV -</i>
<i>-PROVE 3 results to be presented at late breaker session on Saturday,
April 25, 2009-</i><i>-Interim data from two Phase 2 studies of telaprevir indicate
activity across multiple genotypes in treatment-naïve HCV patients-</i><i>-Early data from newly-acquired polymerase inhibitors suggest rapid,
powerful antiviral activity with favorable safety and tolerability
profile-</i>
<i>- Telaprevir registration program on track; VCH-222 enters
multi-dose, 3-day viral kinetic study -</i><i>- VX-770 will start registration program in CF patients with G551D
mutation -</i><i>-Vertex ends first quarter with $869 million of cash, cash
equivalents and marketable securities-</i>
CAMBRIDGE, Mass., Apr 03, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its first quarter 2009 financial results on Thursday, April 16, 2009 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.
CAMBRIDGE, Mass., Mar 30, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at Citi's 4 th Annual Biotech Day on Wednesday, April 1, 2009 at 2:40 p.m. EDT and at the Canaccord Adams Hepatitis C Conference on
<i><b>- Primary endpoints of safety and tolerability to be evaluated in
Phase 2a clinical trial -</b></i><i><b>- Measurements of CFTR function to be assessed as secondary
endpoints -</b></i><i><b>- Trial to enroll approximately 90 patients with the F508del CFTR
mutation -</b></i>
<i><b>- PROVE 3 SVR results accepted as late-breaker oral presentation -</b></i><i><b>- First clinical results for VCH-222 in HCV patients accepted as
poster presentation -</b></i>
CAMBRIDGE, Mass., Mar 13, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Cowen & Company 29 th Annual Health Care Conference on Tuesday, March 17, 2009 at 2:25 p.m. EDT.
<i>- Vertex to acquire privately-held ViroChem Pharma in cash and stock
transaction -</i><i>- Two HCV polymerase inhibitors, VCH-222 and VCH-759, have
demonstrated significant antiviral activity in early clinical trials -</i><i>- First STAT-C combination trial with telaprevir planned for 2H 2009
start -</i>